Stryker Corporation $SYK Shares Sold by Campbell Newman Asset Management Inc.

Campbell Newman Asset Management Inc. trimmed its position in shares of Stryker Corporation (NYSE:SYK) by 5.1% during the second quarter, Holdings Channel reports. The firm owned 59,656 shares of the medical technology company’s stock after selling 3,218 shares during the quarter. Stryker comprises approximately 1.4% of Campbell Newman Asset Management Inc.’s holdings, making the stock its 27th biggest position. Campbell Newman Asset Management Inc.’s holdings in Stryker were worth $18,782,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of SYK. Sankala Group LLC acquired a new position in shares of Stryker during the 4th quarter worth $26,000. Godfrey Financial Associates Inc. acquired a new stake in Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new stake in Stryker in the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new position in Stryker during the 4th quarter valued at about $27,000. Finally, Gables Capital Management Inc. acquired a new position in Stryker during the second quarter worth about $25,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SYK. Royal Bank Of Canada reduced their price target on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Citigroup reaffirmed a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a report on Friday, May 1st. Finally, Truist Financial boosted their price target on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Trading Up 2.9%

Shares of SYK opened at $331.32 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The company has a market capitalization of $127.08 billion, a PE ratio of 34.33, a price-to-earnings-growth ratio of 2.05 and a beta of 0.76. The stock has a fifty day moving average of $329.10 and a two-hundred day moving average of $331.47. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is 36.48%.

Insider Buying and Selling at Stryker

In related news, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 351,267 shares of company stock worth $118,197,701 in the last 90 days. 4.60% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.